There are several programs that can provide financial assistance to your patients taking UPTRAVI ®. For information on these programs, call a Janssen CarePath Care Coordinator at 866-228-3546, Monday-Friday, 8 AM to 8 PM ET. Commercially insured Support for patients using commercial or private insurance to pay for medication
Full Answer
What is Uptravi used to treat?
Uptravi (selexipag) is a member of the agents for pulmonary hypertension drug class and is commonly used for Pulmonary Hypertension. This Uptravi price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Is there a generic version of Uptravi?
See generic Uptravi availability. Uptravi (selexipag) is a member of the agents for pulmonary hypertension drug class and is commonly used for Pulmonary Hypertension. The cost for Uptravi oral tablet 200 mcg is around $13,738 for a supply of 60 tablets, depending on the pharmacy you visit.
How do I get an offer from Uptravi?
Uptravi offers may be in the form of a printable coupon, rebate, savings or copay card, trial offer, or free samples. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office.
What is the cost of Uptravi 200 MCG tablets?
The cost for Uptravi oral tablet 200 mcg is around $11,049 for a supply of 60 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is UPTRAVI used to treat?
What is UPTRAVI®? UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs. UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.
Who manufactures UPTRAVI?
UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Ltd. 2.
What is the cost of selexipag?
Uptravi (selexipag) is a member of the agents for pulmonary hypertension drug class and is commonly used for Pulmonary Hypertension....Oral Tablet.QuantityPer unitPrice60$356.00$21,359.80
Is UPTRAVI a specialty drug?
UPTRAVI® is not available through retail pharmacies. UPTRAVI® is distributed to patients by mail through a specialty pharmacy rather than through a retail pharmacy. When you enroll your patients, they are connected to a specialty pharmacy based on their health insurance plans or their healthcare teams' preference.
Is there a generic for UPTRAVI?
No. There is currently no therapeutically equivalent version of Uptravi available in the United States. Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uptravi. These medications may be counterfeit and potentially unsafe.
What is the generic name for UPTRAVI?
Generic Name: selexipag Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH).
What class of drug is Uptravi?
Uptravi is a prescription medicine used to treat the symptoms of Pulmonary Arterial Hypertension (PAH) Disease Progression. Uptravi may be used alone or with other medications. Uptravi belongs to a class of drugs called PAH, Prostacyclin Agonists.
What happens if you stop taking UPTRAVI?
Uptravi injection is given in a vein by a healthcare provider if you are unable to take medicine by mouth. You should not stop taking Uptravi without your doctor's advice. Stopping suddenly may make your condition worse. Store tablets at room temperature away from moisture and heat.
What is the difference between UPTRAVI and Opsumit?
Uptravi and Opsumit belong to different drug classes. Uptravi is a prostacyclin receptor agonist and Opsumit is an endothelin receptor antagonist. Side effects of Uptravi and Opsumit that are similar include headache and low levels of iron in the blood (anemia).
Can you cut UPTRAVI?
Do not split, crush, or chew tablets. If a dose of medication is missed, patients should take a missed dose as soon as possible unless the next dose is within the next 6 hours. If treatment is missed for 3 days or more, restart UPTRAVI at a lower dose and then retitrate.
What is the difference between UPTRAVI and Opsumit?
Uptravi and Opsumit belong to different drug classes. Uptravi is a prostacyclin receptor agonist and Opsumit is an endothelin receptor antagonist. Side effects of Uptravi and Opsumit that are similar include headache and low levels of iron in the blood (anemia).
Is UPTRAVI a brand name?
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).
What happens if you stop taking UPTRAVI?
Uptravi injection is given in a vein by a healthcare provider if you are unable to take medicine by mouth. You should not stop taking Uptravi without your doctor's advice. Stopping suddenly may make your condition worse. Store tablets at room temperature away from moisture and heat.
What drug class is UPTRAVI?
Uptravi belongs to a class of drugs called PAH, Prostacyclin Agonists.
What is a tam in PAH?
TAMs provide education on the payer approval process to help your patients start and stay on the prescribed Janssen PAH therapy.
How to contact Janssen Carepath?
Call a Janssen CarePath Care Coordinator at 866-228-3546, or visit JanssenCarePath.com for more information on affordability programs that may be available.
What is JJPAF in healthcare?
(JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 833-919-3510 (toll free) / 308-920-4358 (direct dial), (Monday–Friday, 9:00 AM –6:00 PM ET) or visit the foundation website at JJPAF.org .
Does Janssen CarePath pay for UPTRAVI?
Janssen CarePath Oral PAH Savings Program can help eligible patients save on their out-of-pocket medication costs for UPTRAVI ®. Your eligible patients will pay $5 per prescription fill with a $20,000 maximum program benefit per calendar year across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. See full eligibility requirements.
How much does Uptravi cost?
Eligible patients using commercial or private insurance can save on out-of-pocket medication costs for UPTRAVI. Eligible patients pay $5 per prescription fill with a $20,000 maximum program benefit per calendar year across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement.
What is UPTRAVI used for?
UPTRAVI ® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs. UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.
How to report UPTRAVI side effects?
You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Keep UPTRAVI and all other medicines away from children.
What is a PAH companion program?
The Janssen CarePath PAH Companion Program provides one-on-one educational support to help you start and stay on your prescribed Janssen medication and resources to help you partner with your healthcare team to better manage your pulmonary arterial hypertension (PAH).
How often should I take Uptravi?
Take UPTRAVI exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI twice a day. Taking UPTRAVI with food may help you tolerate UPTRAVI better
How to talk to a PAH companion?
Patients who have enrolled can talk to a PAH Companion by calling 1-866-300-1818, Mon-Fri, 8 AM -9 PM ET.
How to contact Janssen Carepath?
Call a Janssen CarePath Care Coordinator at 866-228-3546 or visit JanssenCarePath.com for more information about affordability programs and independent foundations † that may have funding available. †Independent co-pay assistance foundations have their own rules for eligibility.
What is Uptravi patient guide?
A patient guide that highlights the important steps and information about titration with UPTRAVI ®.
What is UPTRAVI used for?
UPTRAVI ® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
How many times can you increase uptravi?
Increase UPTRAVI ® dose, up to twice , when co-administered with rifampin. Reduce UPTRAVI ® when rifampin is stopped.
How often should I take Uptravi?
Administer UPTRAVI ® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI ® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI ® for injection as an 80-minute intravenous infusion.
What is a PAH companion?
The Janssen CarePath PAH Companion* Program provides one-on-one educational support to help patients start and stay on their prescribed Janssen medication and resources to help them partner with their healthcare team to better manage their pulmonary arterial hypertension (PAH).
What is the phone number for PAH?
As part of the program, PAH Companions are ready to answer patients’ questions. Patients who have enrolled can talk to a PAH Companion by calling 866-300-1818, Monday-Friday, 8 AM to 9 PM ET.
Does Uptravi cause hyperthyroidism?
Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI ® Tablets and in none of the patients on placebo.
What is Uptravi used for?
Uptravi (selexipag) is a member of the agents for pulmonary hypertension drug class and is commonly used for Pulmonary Hypertension.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Is Uptravi a generic?
Uptravi is available as a brand name drug only, a generic version is not yet available. For more information, read about generic Uptravi availability . This Uptravi price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Welcome to Janssen CarePath
Janssen CarePath is here to help answer your questions about treatment with UPTRAVI ®. Once you and your doctor have decided UPTRAVI ® is right for you, we will give you resources that may help you get started and stay on track.
Getting Started
Janssen CarePath can review your health plan benefits and insurance coverage for UPTRAVI ® and offer treatment education resources.
Staying on Track
We understand how important it is for you to take the Janssen medication your doctor prescribed. Janssen CarePath provides ongoing support that may help you stay on track with your UPTRAVI ® treatment.
Resources
Documents and websites to help you with cost support, coverage, and more.
Resources
The following resources are designed to help you as you start treatment with UPTRAVI ®. You will also find common questions and answers about Janssen CarePath and UPTRAVI ® .
Enrollment
Patient Authorization Form [PDF] - Allows you to authorize the use of your personal information for Janssen patient support programs.
Patient Support
Dose Adjustment Phase Guide [PDF] - A guide that highlights important steps and information about titration with UPTRAVI ® .
Cost Support
Janssen CarePath Oral PAH Savings Program Overview [PDF] - Provides information on the Janssen CarePath Savings Program for UPTRAVI ® and eligibility requirements for enrolling in the program.
Coverage
Medicare Open Enrollment Guide [PDF] - Even if you keep the same health plan, your benefits can change. This guide can help you review your coverage and make changes if needed during the open enrollment period so you can stay on treatment in the new benefit period.
Johnson & Johnson Patient Assistance Foundation, Inc
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) - An independent, nonprofit organization that gives eligible patients free prescription medicines donated by Johnson & Johnson companies.
What is UPTRAVI used for?
UPTRAVI ® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
How much uptravi should I take daily?
Recommended starting dose is 200 mcg twice daily for UPTRAVI ® Tablets. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.
How many times can you increase uptravi?
Increase UPTRAVI ® dose, up to twice , when co-administered with rifampin. Reduce UPTRAVI ® when rifampin is stopped.
How often should I take Uptravi?
Administer UPTRAVI ® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI ® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI ® for injection as an 80-minute intravenous infusion.
What percentage of patients had idiopathic and heritable PAH?
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).
Is Uptravi effective in PAH?
Effectiveness of UPTRAVI ® Tablets was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.
Does Uptravi cause hyperthyroidism?
Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI ® Tablets and in none of the patients on placebo.
What is UPTRAVI used for?
What is UPTRAVI ® (selexipag)? UPTRAVI ® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1) , which is high blood pressure in the arteries of your lungs.
How to report side effects of Uptravi?
The most common side effects are: Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI ®. For more information, ask your doctor or pharmacist. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Can Uptravi cause side effects?
UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.
Is Uptravi safe for children?
UPTRAVI ® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH. It is not known if UPTRAVI ® is safe and effective in children. Important Safety Information For UPTRAVI ®.
Contraindications
Warnings and Precautions
- Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI®.
Adverse Reactions
- Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing (12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%). These adverse reactions are …
Drug Interactions
- Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI® with strong inhibitors of CYP2C8 is contraindicated. Concomitant administration of UPTRAVI® with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant e…
Drug Interactions
- CYP2C8 Inhibitors
Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI®with strong inhibitors of CYP2C8 is contraindicated. Concomitant administrati… - CYP2C8 Inducers
Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase UPTRAVI® dose, up to twice, when co-administered with rifampin. Reduce UPTRAVI®when rifampin is stopped.
Dosage and Administration
- Recommended Dosage
Recommended starting dose is 200 mcg twice daily for UPTRAVI® Tablets. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcgtwice daily. If dose is not tolerated, reduce to the previ… - Patients With Hepatic Impairment
For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of UPTRAVI® Tablets is 200 mcg once daily. Increase by 200 mcg once daily at weekly intervals, as tolerated. Avoid use of UPTRAVI®in patients with severe hepatic impairment (Child-Pugh class C).
Additional Important Safety Information For Uptravi® IV
- Use UPTRAVI®for injection in patients who are temporarily unable to take oral therapy. Administer UPTRAVI® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI®for injection as an 80-minute intravenous infusion. Adverse Reactions: Inf…